New clinical trial to test drug for diabetes in reducing risk of alzheimer’s dementia

alzheimers
Credit: Pixabay/CC0 Public Domain

A new study led through a collaboration between the Diabetes Trials Unit and the Department of Psychiatry at the University of Oxford, and the global healthcare company, Novo Nordisk, will examine whether semaglutide, a tablet used to treat diabetes, can change the course of the earliest change in the brains of people at risk of developing Alzheimer’s dementia

The Impact of Semaglutide in Amyloid Positivity (ISAP) trial will recruit 88 volunteers currently living without dementia from five UK clinical sites in: Oxford, Imperial College London, University College London, Exeter, and Bristol. Participants will have a PET (Positron…

Read more…